Details of Disease

General Information of Disease (ID: DISESTHB)

• Disease Name: Glioblastoma of brain
• Synonyms: grade IV brain astrocytic tumour; grade IV brain astrocytic tumor; grade IV brain astrocytic neoplasm; grade IV astrocytic tumour of the brain; grade IV astrocytic tumour of brain; grade IV astrocytic tumor of the brain; grade IV astrocytic tumor of brain; grade IV astrocytic neoplasm of the brain; grade IV astrocytic neoplasm of brain; glioblastoma multiforme of the brain; glioblastoma multiforme of brain; glioblastoma (disease) of brain; brain glioblastoma multiforme (disease); brain glioblastoma multiforme; brain glioblastoma (disease); brain glioblastoma
• Disease Class: 2A00: Brain cancer
• Definition: A WHO grade IV malignant astrocytic tumor that arises from the brain, usually the cerebral hemispheres. It is characterized by the presence of poorly differentiated astrocytes, cellular polymorphism, nuclear atypia, and increased mitotic activity. The prognosis is poor.
• Disease Hierarchy:
  DISE8B6O: Brain glioma
  DISI0V5E: Glioblastoma
  DISESTHB: Glioblastoma of brain
• ICD Code:
  ICD-11: ICD-11: 2A00.00
  ICD-10: ICD-10: C71
  Expand ICD-11: '2A00.00
  Expand ICD-10: 'C71
• Disease Identifiers:
  MONDO ID: MONDO_0002501
  UMLS CUI: C0349543
  MedGen ID: 138100
  SNOMED CT ID: 276828006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
DTI-015	DMXZRW0	Approved	Small molecular drug	[2]
Temozolomide	DMKECZD	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 23 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DSP-7888	DM781D6	Phase 3	Vaccine	[4]
Marizomib	DME9QGW	Phase 3	Small molecular drug	[5]
Ofranergene obadenovec	DMBLHIS	Phase 3	Gene therapy	[6]
Trans-sodium crocetinate	DMQOQBL	Phase 3	Small molecular drug	[7]
Ad-RTS-hIL-12	DMCNTFW	Phase 2	Gene therapy	[8]
AV-GBM-1	DMGP6EP	Phase 2	Vaccine	[9]
Depatuxizumab	DM7GPMB	Phase 2	NA	[10]
ERC1671	DMDPI1G	Phase 2	Vaccine	[11]
GDC-0084	DMA9SEY	Phase 2	NA	[12]
INO-5401	DMXX3EW	Phase 2	Vaccine	[13]
ITI-1000	DMS9H2X	Phase 2	Vaccine	[14]
MDNA55	DMXV2UU	Phase 2	NA	[15]
PVSRIPO	DM3ZLTB	Phase 2	Vaccine	[16]
SL-701	DMC8NDX	Phase 2	NA	[17]
SurVaxM	DMAIGTE	Phase 2	NA	[18]
TB-403	DMDPBMH	Phase 2	NA	[19]
GLR2007	DM7DWLY	Phase 1/2	NA	[20]
VBI-1901	DM8EN32	Phase 1/2	NA	[21]
CC-90010	DMKH3Z9	Phase 1	NA	[22]
D2C7	DMIMK84	Phase 1	Antibody	[23]
INB-200	DMYR8AG	Phase 1	Cell therapy	[24]
MB-108	DMHZQ55	Phase 1	Oncolytic virus therapy	[25]
OS2966	DMS8NM5	Phase 1	Antibody	[26]

This Disease is Treated as An Indication in 3 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KL001	DMHX1LA	Preclinical	Small molecular drug	[27]
SHP656	DM8DYJQ	Preclinical	Small molecular drug	[27]
TH301	DM4BDGW	Preclinical	Small molecular drug	[27]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
UNC2025	DMCU59W	Investigative	Small molecular drug	[28]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CLEC5A	OT19WV30	Strong	Biomarker	[29]

References

• [1] Synchronous glioblastoma and brain metastases: illustrative case. J Neurosurg Case Lessons. 2022 Mar 21;3(12):CASE21714.
• [2] Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol). Neuro Oncol. 2007 Jan;9(1):12-9.
• [3] Temozolomide FDA Label
• [4] ClinicalTrials.gov (NCT03149003) A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04406272) VB-111 in Surgically Accessible Recurrent/Progressive GBM. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT03393000) Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (INTACT). U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT04006119) Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT03400917) Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT02343406) Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2). U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT01903330) ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT03522298) Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma. U.S. National Institutes of Health.
• [13] ClinicalTrials.gov (NCT03491683) INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM). U.S. National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of Immunomic Therapeutics.
• [15] ClinicalTrials.gov (NCT02858895) Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT04479241) PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT02078648) Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT04013672) Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT01622764) 89Zr-RO5323441 PET Imaging in Glioblastoma. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT04444427) Evaluation of GLR2007 for Advanced Solid Tumors. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT03382977) Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT04047303) CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma. U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT02303678) D2C7 for Adult Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.
• [24] Clinical pipeline report, company report or official report of IN8bio.
• [25] Clinical pipeline report, company report or official report of Mustang Bio.
• [26] ClinicalTrials.gov (NCT04608812) Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection. U.S. National Institutes of Health.
• [27] Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
• [28] MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
• [29] C-type lectin domain family 5, member A (CLEC5A, MDL-1) promotes brain glioblastoma tumorigenesis by regulating PI3K/Akt signalling.Cell Prolif. 2019 May;52(3):e12584. doi: 10.1111/cpr.12584. Epub 2019 Mar 4.